bretylium is thus currently approved as a first-line agent for prophylaxis and treatment of ventricular fibrillation , and as a second-line agent for ventricular tachycardia and other prefibrillatory ventricular arrhythmias .
C0042510
ventricular fibrillation
C0085612
ventricular arrhythmias